The innovative medicine leader in the field of immune-related diseases. The team members have internationalized background and they have introduced over 30 overseas products to China in their own field. It leads the global R&D of over 20 new medicines and gains NDA in 28 countries, 6 IND of innovative products in China and America. The company has wholly-owned subsidiaries in Shanghai, Hangzhou and Beijing. Other product pipelines include the first or best candidate medicine of the same kind. There will be several global registered clinical trials for multiple indications for IMG-020.
Location: China, Shanghai
Employees: 51-200
Total raised: $21M
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | triwise | en.triwise... |
| - | Panacea Ve... | panaceaven... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.09.2020 | Series B | $21M | - |
Mentions in press and media 22
| Date | Title | Description | Source |
| 02.02.2024 | Inmagene Exercises Option to Obtain Exclusive Worldwide Lice... | Inmagene exercised its option under the previously announced collaboration agreement to obtain an ex... | en.prnasia... |
| 13.10.2023 | Inmagene Doses First Patient in Phase 2a Trial of IMG-007, a... | IMG-007 is a novel anti-OX40 monoclonal antibody (mAb) engineered for potentially once every 12 week... | en.prnasia... |
| 21.09.2023 | Inmagene announces formation of Celexor Bio based on its ant... | SAN DIEGO, Sept. 21, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals (Inmagene), a clinical-stage b... | en.prnasia... |
| 05.09.2023 | David Topper Joined Inmagene as CFO | SAN DIEGO, Sept. 5, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene"), a clini... | en.prnasia... |
| 28.04.2023 | IMG-004 demonstrated extended half-life and durable pharmaco... | SAN DIEGO, SHANGHAI and SYDNEY, April 28, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("In... | en.prnasia... |
| 20.03.2023 | Izokibep Phase 2b/3 Hidradenitis Suppurative Data Presented ... | At 12 weeks, participants achieved high orders of HiSCR responses (HiSCR75 and above), including 33%... | en.prnasia... |
| 06.02.2023 | Inmagene receives IND clearance for IMG-008, a long-acting I... | SAN DIEGO, SHANGHAI and SYDNEY, Feb. 6, 2023 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inma... | en.prnasia... |
| 09.08.2022 | Inmagene and HUTCHMED Announce First Participant in Global P... | SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceu... | globenewsw... |
| 09.08.2022 | Inmagene and HUTCHMED Announce First Participants in Global ... | SAN DIEGO, SHANGHAI and HONG KONG, Aug. 9, 2022 /PRNewswire/ -- Inmagene Biopharmaceutical ("In... | en.prnasia... |
| 06.07.2022 | Inmagene and HUTCHMED Announce First Participants in Global ... | SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("... | en.prnasia... |
Show more